MannKind (NASDAQ:MNKD) Rating Lowered to Hold at Wall Street Zen

MannKind (NASDAQ:MNKD) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of MannKind in a research note on Thursday, January 22nd. Truist Financial set a $9.00 target price on MannKind in a research note on Monday, November 24th. Royal Bank Of Canada restated a “sector perform” rating and set a $3.50 price target (down from $7.50) on shares of MannKind in a report on Friday. Leerink Partners started coverage on MannKind in a research note on Thursday, November 13th. They issued an “outperform” rating and a $7.00 price objective for the company. Finally, Zacks Research lowered shares of MannKind from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, MannKind presently has an average rating of “Moderate Buy” and a consensus target price of $9.21.

MannKind Price Performance

Shares of NASDAQ:MNKD opened at $3.28 on Friday. The firm has a market capitalization of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84. MannKind has a 1 year low of $2.93 and a 1 year high of $6.51. The firm’s 50-day moving average is $5.55 and its two-hundred day moving average is $5.37.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a net margin of 1.68% and a negative return on equity of 11.12%. The business had revenue of $111.96 million during the quarter, compared to analysts’ expectations of $99.85 million. During the same period in the previous year, the business posted $0.03 EPS. The company’s revenue for the quarter was up 45.8% compared to the same quarter last year. Analysts expect that MannKind will post 0.1 EPS for the current fiscal year.

Insider Activity at MannKind

In related news, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the transaction, the insider directly owned 985,007 shares of the company’s stock, valued at $6,235,094.31. This represents a 4.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Castagna sold 65,804 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total transaction of $395,482.04. Following the completion of the transaction, the chief executive officer owned 2,504,792 shares in the company, valued at $15,053,799.92. This represents a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 262,846 shares of company stock valued at $1,546,840. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On MannKind

A number of institutional investors and hedge funds have recently bought and sold shares of MNKD. Mercer Global Advisors Inc. ADV purchased a new position in shares of MannKind during the fourth quarter worth about $70,000. Voloridge Investment Management LLC grew its stake in MannKind by 50.8% during the 4th quarter. Voloridge Investment Management LLC now owns 1,861,046 shares of the biopharmaceutical company’s stock worth $10,552,000 after buying an additional 626,878 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in MannKind during the fourth quarter worth approximately $182,000. Polymer Capital Management US LLC acquired a new position in MannKind during the fourth quarter worth approximately $168,000. Finally, Man Group plc lifted its stake in MannKind by 80.9% in the fourth quarter. Man Group plc now owns 178,494 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 79,843 shares during the last quarter. 49.55% of the stock is owned by hedge funds and other institutional investors.

MannKind News Summary

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.